common.study.topics.clinical

Testing Treatment for Breast Cancer

common.study.values.description

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Laboratory Biomarker Analysis

Correlative studies

Patient Observation

Undergo standard monitoring

Biological - Pembrolizumab

Given IV

Quality-of-Life Assessment

Ancillary studies

Questionnaire Administration

Ancillary studies

Radiation - Radiation Therapy

Undergo radiation therapy

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

common.study.values.clinical-trial-id

NCT02954874

participant.views.study.view.id

xbo0Xd